- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05467722
Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543
November 28, 2022 updated by: Concert Pharmaceuticals
A Phase 1 Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of CTP-543 (Deuruxolitinib Phosphate)
This is an open-label, single-dose, single-period, parallel group designed study to determine the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of CTP-543 and its major metabolites following administration of a single 12 mg oral dose of CTP-543.
Study Overview
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Orlando, Florida, United States, 32809
- Orlando Clinical Research Center
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- Alliance for Multispecialty Research, LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult males or females aged 18-75
- Body mass index (BMI) ≥ 18.0 and ≤ 42.0 kg/m2 at the time of screening
- If of reproductive age, willing and able to use a medically highly effective form of birth control 30 days prior to first dose, during the study and for 30 days following last dose of study medication
- Capable of giving informed consent and complying with study procedures
Additional Inclusion Criteria for Subjects with Hepatic Impairment:
- For moderate hepatic impairment, the subject must have a Child-Pugh score of 7 to 9 at the time of screening. For mild hepatic impairment, the subject must have a Child- Pugh score of 5 to 6 at the time of screening.
- No clinically significant change in disease status within the last 30 days before screening
- The subject must have a condition consistent with hepatic impairment and associated symptoms, but otherwise be determined to be healthy in the opinion of the Investigator
- If diabetic, the subject must have the disease controlled
Exclusion Criteria:
- History of any clinically significant medical condition, psychiatric disease, social condition, or illness that might confound the results of the study or poses an additional risk to the subject by their participation in the study
- Known history of any GI surgery or any condition possibly affecting drug absorption
- History of prolonged QT syndrome or a QTc interval with Fridericia's correction (QTcF) > 470 msec for males or QTcF > 480 msec for females at Screening visit.
- Females who are nursing or pregnant prior to drug administration
- Positive for human immunodeficiency virus (HIV)
- Positive results for coronavirus infection (COVID-19) at screening or check-in
- Positive drugs of abuse or alcohol results at screening or check in (Day -1)
Additional Exclusion Criteria for Subjects with Hepatic Impairment:
- History or current diagnosis of uncontrolled or significant cardiac disease
- Gilbert's syndrome, liver transplant, Wilson's disease, autoimmune liver disease, esophageal variceal bleeding within 3 months prior to screening
- Previous diagnosis of hepatocellular carcinoma
- Acute or exacerbating hepatitis, fluctuating or rapidly deteriorating hepatic function
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CTP-543 Treatment - Mild Hepatic Impairment
|
Single 12 mg oral dose administered on Day 1
|
Experimental: CTP-543 Treatment - Moderate Hepatic Impairment
|
Single 12 mg oral dose administered on Day 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Single dose PK exposure: Maximum observed concentration (Cmax)
Time Frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 36, 48 hours post-dose
|
Maximum concentration, obtained directly from the observed concentration versus time data.
|
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 36, 48 hours post-dose
|
Single dose PK exposure: Area Under the Concentration-Time Curve from time zero to the time of the last observed/measured non-zero concentration (AUC0-t)
Time Frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 36, 48 hours post-dose
|
Area under the concentration-time curve from time zero (pre-dose) to time of last measurable concentration (calculated by linear-log trapezoidal summation)
|
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 36, 48 hours post-dose
|
Single dose PK exposure: Area Under the Concentration-Time Curve from time 0 extrapolated to infinity (AUC0-inf)
Time Frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 36, 48 hours post-dose
|
Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinity, calculated by linear-log trapezoidal summation and extrapolated to infinity by addition of the last quantifiable concentration divided by the elimination rate constant
|
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 36, 48 hours post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of Safety and Tolerability following administration of CTP-543
Time Frame: Screening (within 21 days prior to Day 1) through follow-up (7 to 10 days after the final administration of study drug)
|
Number of adverse events, including abnormal clinical laboratory findings, abnormal physical examinations, abnormal ECGs and abnormal vital signs tabulated for each subject
|
Screening (within 21 days prior to Day 1) through follow-up (7 to 10 days after the final administration of study drug)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2022
Primary Completion (Actual)
September 15, 2022
Study Completion (Actual)
September 21, 2022
Study Registration Dates
First Submitted
June 30, 2022
First Submitted That Met QC Criteria
July 18, 2022
First Posted (Actual)
July 20, 2022
Study Record Updates
Last Update Posted (Actual)
November 29, 2022
Last Update Submitted That Met QC Criteria
November 28, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP543.1013
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Impairment
-
PfizerRecruitingHealthy Volunteers | Moderate Hepatic Impairment | Severe Hepatic ImpairmentUnited States
-
GlycoMimetics IncorporatedCompletedModerate Hepatic Impairment | Normal Hepatic FunctionUnited States
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedSevere Hepatic Impairment | Normal Hepatic FunctionBulgaria
-
Agios Pharmaceuticals, Inc.CompletedModerate Hepatic ImpairmentUnited States
-
Bausch Health Americas, Inc.TerminatedSevere Hepatic ImpairmentUnited States
-
Merck Sharp & Dohme LLCCompletedModerate Hepatic ImpairmentUnited States
-
EQRx International, Inc.CompletedSevere Hepatic ImpairmentUnited States
-
PfizerCompleted
-
TakedaCompletedSevere Hepatic ImpairmentUnited States
-
Mitsubishi Tanabe Pharma CorporationCompletedHealthy | Severe Hepatic ImpairmentCzechia, Hungary, Slovakia
Clinical Trials on CTP-543
-
Concert PharmaceuticalsCompletedAlopecia AreataUnited States, Canada
-
Concert PharmaceuticalsCompleted
-
Concert PharmaceuticalsCompletedAlopecia AreataUnited States
-
Concert PharmaceuticalsCompletedAlopecia AreataUnited States
-
Concert PharmaceuticalsCompletedAlopecia AreataSpain, United States, Poland, Canada, France, Germany, Hungary
-
Concert PharmaceuticalsCompletedAlopecia AreataUnited States, Canada, Poland, France, Spain
-
Concert PharmaceuticalsCompletedHealth VolunteersUnited States
-
Concert PharmaceuticalsCompleted
-
Concert PharmaceuticalsEnrolling by invitationAlopecia AreataUnited States, Canada
-
Concert PharmaceuticalsActive, not recruitingAlopecia AreataSpain, Germany, Poland, France, Hungary